Clinical trial of butylphthalide injection combined with edaravone injection in the treatment of patients with acute cerebral infarction
10.13699/j.cnki.1001-6821.2018.04.001
- VernacularTitle:丁苯酞注射液联合依达拉奉注射液治疗急性脑梗死的临床研究
- Author:
Cong CHEN
1
;
Qing-Jie SU
;
Hai-Rong WU
;
Chao-Sheng ZENG
;
Jing-Xia ZHOU
;
Shu LIU
Author Information
1. 海南医学院第二附属医院神经内科
- Keywords:
acute cerebral infarction;
butylphthalide injection;
edaravone injection
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(4):395-398
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effect and safety of butylphthalide injection combined with edaravone injection in the treatment of acute cerebral infarction.Methods A total of 154 patients with acute cerebral infarction were randomly divided into control group (n =77) and treatment group (n =77).Control group was given edaravone injection 30 mg,bid,intravenous drip.Treatment group was given butylphthalide and sodium chloride injection 25 mg,bid,intravenous drip on the basis of control group.All patients were treated for 14 d.The clinical effect,levels of hemorheological indexes,serum endothelin (ET-1),calmodulin (CaM),thromboxane A2 (TXA2),and levels of serum vascular endothelial growth factor (VEGF),VEGF receptor (VEGFR),platelet derived endothelial cell growth factor (PD-ECGF) levels and adverse drug ractions were compared between the two groups.Results After treatment,the total effective rates in treatment group and control group were 84.42％ (65 cases/77 cases) and 70.13 ％ (54 cases/77 cases),with significant difference (P ＜ 0.05).After treatment,the plasma viscosity in treatment group and control group were (1.02 ± 0.14) and (1.29 ± 0.17) mPa · s,whole blood viscosity shear rates were (3.03 ± 0.41) and (3.98 ± 0.56) mPa · s,hematocrit were 0.33 ± 0.04 and 0.42 ± 0.05,platelet aggregation rates were(42.38 ±5.35)％ and(50.43 ± 6.26)％,serum ET-1 were (50.62 ± 6.63) and (62.47 ±8.05) ng · L-1,CaM were(98.65 ± 12.18) and(137.85 ± 16.45) mg · mL-1,TXA2 were (70.02 ± 9.55) and (82.14 ± 11.15)ng · L-1,serum VEGF were (419.36 ± 40.37) and (372.27 ± 39.44) ng · L-1,VEGFR were (405.47 ± 45.36) and (346.56 ± 41.19) ng· L-1,PD-ECGF were (12.47 ± 1.36) and (6.11 ± 0.65) μg · mL-1,all with significant difference (all P ＜ 0.05).The adverse drug reactions were nausea and vomiting,dizziness,drowsiness and heart rate slowing in treatment group and control group.The incidence of adverse drug reactions of treatment group and control group were 14.29％ (11 cases/77 cases) and 10.39％ (8 cases/77 cases),without significant difference (P ＞ 0.05).Conclusion The clinical effect of butylphthalide injection combined with edaravone in the treatment of acute cerebral infarction is exactly,and can effectively improve the indexes of hemorheology,reduce serum levels of ET-1,CaM and TXA2,reduce vascular endothelial damage and prevent thrombosis,increase the levels of serum VEGF,VEGFR,PD-ECGF,and promote neovascularization,with high safety.
